Literature DB >> 29600035

Perspectives on oligometastasis: challenges and opportunities.

Jana Heitmann1, Matthias Guckenberger1.   

Abstract

Year:  2018        PMID： 29600035      PMCID： PMC5863114          DOI： 10.21037/jtd.2017.12.77

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  20 in total

1.  Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004).

Authors:  T Ruers; C Punt; F Van Coevorden; J P E N Pierie; I Borel-Rinkes; J A Ledermann; G Poston; W Bechstein; M A Lentz; M Mauer; E Van Cutsem; M P Lutz; B Nordlinger
Journal:  Ann Oncol       Date:  2012-03-19       Impact factor: 32.976

2.  Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists.

Authors:  Stephen L Lewis; Sandro Porceddu; Naoki Nakamura; David A Palma; Simon S Lo; Peter Hoskin; Drew Moghanaki; Steven J Chmura; Joseph K Salama
Journal:  Am J Clin Oncol       Date:  2017-08       Impact factor: 2.339

Review 3.  Oligometastases revisited.

Authors:  Ralph R Weichselbaum; Samuel Hellman
Journal:  Nat Rev Clin Oncol       Date:  2011-03-22       Impact factor: 66.675

4.  Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).

Authors:  Dirk De Ruysscher; Rinus Wanders; Angela van Baardwijk; Anne-Marie C Dingemans; Bart Reymen; Ruud Houben; Gerben Bootsma; Cordula Pitz; Linda van Eijsden; Wiel Geraedts; Brigitta G Baumert; Philippe Lambin
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

5.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Authors:  David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran
Journal:  Lancet       Date:  2004-05-22       Impact factor: 79.321

6.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

7.  Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.

Authors:  David A Palma; Cornelis J A Haasbeek; George B Rodrigues; Max Dahele; Michael Lock; Brian Yaremko; Robert Olson; Mitchell Liu; Jason Panarotto; Gwendolyn H M J Griffioen; Stewart Gaede; Ben Slotman; Suresh Senan
Journal:  BMC Cancer       Date:  2012-07-23       Impact factor: 4.430

Review 8.  The biology and treatment of oligometastatic cancer.

Authors:  Diane K Reyes; Kenneth J Pienta
Journal:  Oncotarget       Date:  2015-04-20

9.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316

10.  Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.

Authors:  Karel Decaestecker; Gert De Meerleer; Filip Ameye; Valerie Fonteyne; Bieke Lambert; Steven Joniau; Louke Delrue; Ignace Billiet; Wim Duthoy; Sarah Junius; Wouter Huysse; Nicolaas Lumen; Piet Ost
Journal:  BMC Cancer       Date:  2014-09-15       Impact factor: 4.430
View more
  1 in total

Review 1.  The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation.

Authors:  Jinfeng Cui; Li Li; Shuanghu Yuan
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.